Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAKIDV)

Drug Name
Dydrogesterone Drug Info
Synonyms
Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI)
Indication
Disease Entry ICD 11 Status REF
Menstrual disorder GA20.3 Approved [1]
Therapeutic Class
Progesterones
Cross-matching ID
PubChem CID
9051
ChEBI ID
CHEMBL31527
CAS Number
CAS 152-62-5
TTD Drug ID
DMAKIDV
INTEDE Drug ID
DR0556

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Progesterone receptor (PGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [6]
Desogestrel DM27U4Y Contraception QA21 Approved [7]
Ulipristal DMBNI20 Contraception QA21 Approved [8]
Etonogestrel DMKA8J4 Contraception QA21 Approved [9]
Megestrol DMDH9KX Breast cancer 2C60-2C65 Approved [10]
Segesterone acetate; ethinyl estradiol DMFEGB0 Contraception QA21 Approved [11]
Norgestimate DMYP4XC Acne vulgaris ED80 Approved [9]
Medroxyprogesterone DMBGWPH Solid tumour/cancer 2A00-2F9Z Approved [2]
Ethynodiol Diacetate DMZM84R Contraception QA21 Approved [12]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [17]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [20]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [21]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [15]
Verapamil DMA7PEW Angina pectoris BA40 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estrone DM5T6US Acne vulgaris ED80 Approved [23]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [23]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [24]
Quercetin DM3NC4M Obesity 5B81 Approved [25]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [27]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [28]
Plicamycin DM7C8YV Hypercalcaemia 5B91.0 Approved [29]
Testosterone DM7HUNW Hot flushes GA30 Approved [30]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [32]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [33]
Diazepam DM08E9O Alcohol withdrawal Approved [34]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [35]
Desogestrel DM27U4Y Contraception QA21 Approved [35]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [33]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [36]
Quercetin DM3NC4M Obesity 5B81 Approved [37]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [33]
Diazepam DM08E9O Alcohol withdrawal Approved [34]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [39]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [40]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Quercetin DM3NC4M Obesity 5B81 Approved [25]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [41]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [33]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [42]
Testosterone DM7HUNW Hot flushes GA30 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [4]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [33]
Diazepam DM08E9O Alcohol withdrawal Approved [34]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [33]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [45]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [46]
Ethacrynic acid DM60QMR Edema MG29 Approved [44]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Progesterone-induced-blocking factor 1 (PIBF1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [48]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [49]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [50]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [51]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [53]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [49]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [54]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [55]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Agonist [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2) OT3K7HY5 DHB2_HUMAN Gene/Protein Processing [4]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [4]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [4]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [4]
Progesterone-induced-blocking factor 1 (PIBF1) OTCBT1A1 PIBF1_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2878).
2 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
3 Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74.
4 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
5 Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005 Aug;112(8):1096-101. doi: 10.1111/j.1471-0528.2005.00633.x.
6 Clinical pipeline report, company report or official report of lipocine.
7 Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
8 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
9 Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
10 Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
11 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12 Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
13 Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
24 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
25 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
26 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
27 Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
28 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
29 SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006 Oct;75(4):605-14.
30 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
31 Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
32 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
33 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
34 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
35 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
36 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
37 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
38 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
39 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
40 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
41 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
42 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
43 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
44 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
45 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
46 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
47 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
48 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
49 Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007 Aug;48(8):1610-7. doi: 10.1080/10428190701471999.
50 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
51 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
52 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
53 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
54 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
55 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.